-
2023-506752-24-00
5
2021-08-05
Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
-
2022-502100-70-00
10
2021-06-23
Participants with Microsatellite Instability-High (MSI-H) or Mismatch
-
2023-510389-28-00
5
2021-06-14
short bowel syndrome
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2023-505659-27-00
4
2020-10-21
Multiple Myeloma
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2023-505170-15-00
5
2020-05-15
Adult Subjects With Late Onset Pompe Disease (LOPD)
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2023-505477-33-00
5
2019-06-18
Psoriatic Arthritis
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-506830-66-00
4
2019-05-29
SGA - small for gestational age children
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-503254-12-00
5
2019-03-06
Metastatic Prostate Cancer
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2022-501817-29-00
5
2018-11-27
High Risk Non-muscle invasive bladder cancer
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis